AngioDynamics, Inc. (ANGO) Stock Analysis

AngioDynamics markets its NanoKnife irreversible electroporation ablation system, Auryon atherectomy system, and AlphaVac/AngioVac thrombectomy devices through its Med Tech segment, alongside angiographic catheters, drainage products, and vascular access ports in its Med Device segment, manufacturing from two leased facilities in Queensbury and Glens Falls, New York. NanoKnife received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024, and international distributors generated approximately 74% of the company's international revenue in fiscal 2025.

AngioDynamics earns revenue from device sales to hospitals and physicians who bill Medicare, Medicaid, and private third-party payors for the procedures in which its products are used, selling directly in the United States and through third-party distributors internationally, particularly in China, Japan, Brazil, the Middle East, and parts of Europe. The company manufactures many products in-house at its Queensbury and Glens Falls, New York facilities but is executing a restructuring plan, expected to complete in the third quarter of fiscal 2026, that shifts portions of manufacturing to third-party partners in Costa Rica, Latvia, Italy, Israel, and China, including a supply agreement with Biomerics in Costa Rica. Because reimbursement for many disposable products is bundled into fixed procedure payments rather than separately reimbursed, hospital purchasing decisions increasingly hinge on price alongside clinical outcomes, particularly as group purchasing organizations and integrated health delivery networks consolidate buying power.